Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04756141 · ClinicalTrials.gov registry record · NA
CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT04756141: Completed NA study, sponsored by Mayo Clinic.
NCT04756141 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04756141, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research is to determine if CGM (continuous glucose monitors) used in the hospital in patients with COVID-19 and diabetes treated with insulin will be as accurate as point of care (POC) glucose monitors. Also if found to be accurate, CGM reading data will be used together with POC glucometers to dose insulin therapy.
Interventions
- DEVICE Continuous Glucose Monitor (CGM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2022-08-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04756141
The ClinicalTrials.gov registry entry for NCT04756141 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Continuous Glucose Monitor (CGM) is the first listed.
NCT04756141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04756141 about?
NCT04756141 is a clinical study titled "CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))". The purpose of this research is to determine if CGM (continuous glucose monitors) used in the hospital in patients with COVID-19 and diabetes treated with insulin will be as accurate as point of care (POC) glucose monitors. Also if found to be accurate, CGM reading data will be used together with PO...
What is the current status of trial NCT04756141?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2021-03-03. Estimated completion is 2022-08-24.
What interventions are being tested in trial NCT04756141?
The interventions under investigation include: Continuous Glucose Monitor (CGM) (DEVICE).
Who is sponsoring clinical trial NCT04756141?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.